Coherus Oncology stock sharpens esophageal cancer strategy
Published on 11/17/2026 at 22:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCoherus sharpens oncology focus
- Management selected esophageal cancer as the lead indication for tagmokitug and plans an accelerated-approval path.
- Interim results showed a 33% confirmed response rate in second-line disease, while LOQTORZI quarterly revenue reached 14 million US dollars.
- Cost reductions lowered quarterly cash burn by 6 million to 7 million US dollars.
Coherus Oncology is narrowing its development strategy around tagmokitug and esophageal cancer after presenting updated clinical results at the Jefferies Global Healthcare Conference on Monday, November 16. A Reuters transcript published by Investing.com said management plans to pursue accelerated approval, fast-track status and breakthrough designation for the program in second-line esophageal cancer.
In first-line esophageal cancer, the company reported a 75% confirmed overall response rate across the study population and a 100% response rate among patients with high PD-L1 expression. In second-line disease, tagmokitug combined with toripalimab produced a 33% confirmed response rate and a 44% unconfirmed response rate. Progression-free survival was 5.5 months, compared with 2.5 to 3.5 months for standard chemotherapy, according to the transcript.
Regulatory path and operating changes
Coherus said it is preparing an IND package for filing by year-end. The planned second-line study would compare tagmokitug plus toripalimab with physician-choice chemotherapy in patients whose disease progressed after first-line PD-1 treatment and chemotherapy. The proposed trial would use overall response rate as its primary endpoint, with progression-free and overall survival as secondary endpoints.
LOQTORZI remains the commercial anchor in nasopharyngeal cancer. Quarterly revenue was about 14 million US dollars, near the company's 15 million US dollar target, while management sees potential for more than 40 million US dollars per quarter over the longer term. Coherus also reduced headcount from about 140 to about 100 employees and said the move lowered quarterly cash burn by 6 million to 7 million US dollars.
Coherus Oncology stock traded at 0.45 euros on Lang & Schwarz at 22:41 CET on Tuesday, November 17, 2026.
Coherus Oncology at a glance
- Company: Coherus Oncology, Inc.
- ISIN: US19249H1032
- Ticker: CHRS
- Home exchange: Nasdaq
- Lang & Schwarz quote: 0.45 euros on Tuesday, November 17, 2026, at 22:41 CET
U.S. biotechnology shares trade within the broader Nasdaq Composite environment.
